ClinicalTrials.gg
CompletedNCT03445494Updated Sep 7, 2023

Shoulder Abduction Brace Against Normal Sling After Arthroscopical Rotator Cuff Suture.

An interventional study of Brace and Normal sling in Supraspinatus Injury, sponsored by Christian Candrian. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 72 Years. Per ClinicalTrials.gov, last updated 2023-09-07.

Sponsored by Christian Candrian · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 72 Years
Sex
All
01

Study summary

The patient undergoes arthroscopic surgery to treat rotator cuff injury. At the end of the surgery, the patient will be randomized into group A (brace) or group B (normal sling).

Both groups will be also treated according to standard of care with physiotherapy and progressive introduction of movements.

Read the detailed description

The patient undergoes arthroscopic surgery to treat rotator cuff injury. At the end of the surgery, the patient will be randomized into group A (brace) or group B (normal sling).

Both groups will then perform only passive movements according to pain for the first 6 weeks supported by the physiotherapy, according to standard therapy. The following six weeks passive movements will be associated with active movements . No brace nor normal sling will be used anymore.

Patients are in study for 6 months. During this period quality of life and pain questionnaires are submitted to the patients and a MRI will be done at the end of the study.

02

Conditions studied

  • Supraspinatus Injury
03

In context

Lead sponsor

Christian Candrian is the lead sponsor of 7 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 72 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females between 18 and 65 years old;
  • Presence of an isolated lesion of supraspinatus that can be documented with the MRI and which can be treated surgically by arthroscopy;
  • Presence of a supraspinatus lesion according to the Patte criteria with stage 1, 2 or 3 frontal plane ;
  • Presence of adipose degeneration ≤ 2 according to Goutallier;
  • Written to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Presence of a lesion of other rotator cuff tendons;
  • Previous surgical procedures of the shoulder;
  • Presence of a massive lesion, therefore irreparable, of the cuff detected intra-operatively and not observed during preoperative MRI;
  • Presence of relapsing shoulder dislocations;
  • Presence of lesions of the glenoidine cercine that require intervention;
  • Difficulties to follow the rehabilitation programs;
  • Presence of neoplastic diseases, metabolic diseases, inflammatory and systemic diseases, diseases and patients;
  • State of pregnancy (presumed or established) or breastfeeding.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Brace

    After surgery the patient must wear the brace for 6 weeks, for the first 3 weeks during day and night and for the following 3 weeks only at night

    Procedure: Brace

  • Experimental
    Normal sling

    After surgery the patient must wear the normal sling for two weeks

    Procedure: Normal sling

Interventions

  • ProcedureBrace

    A brace to be weared according to protocol

  • ProcedureNormal sling

    A normal sling to be weared according to protocol

06

What researchers measure

Primary outcomes

  1. Efficacy in the rehabilitative therapy

    The primary objective of the study is to evaluate two different rehabilitative therapies. Efficacy is measured with a pre and post MRI

    Time frame: 6 months

Secondary outcomes

  1. Quality of life assessment

    Evaluation of the quality of live in both groups through Constant Quality of Life questionnair up to 6 months

    Time frame: 6 months

  2. re-rupture rate of the supraspinatus tendon

    Evaluation of the re-rupture of the supraspinatus tendon though a follow up MRI at 6 months

    Time frame: 6 months

07

Study locations

1 site
  • Ente Ospedaliero Cantonale
    Lugano, 6900, Switzerland
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Jul 2023, 66 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2018
First posted
Feb 26, 2018
StartActual
Jan 10, 2018
Primary completionActual
Jul 11, 2023
CompletionActual
Jul 11, 2023
Last update
Sep 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03445494
Lead sponsor
Christian Candrian
Collaborators
Clinical Trial Unit Ente Ospedaliero Cantonale
Responsible party
Christian Candrian (Deputy Head of Surgery and Orthopedy, Ente Ospedaliero Cantonale, Bellinzona) — Sponsor-investigator
First posted
Feb 26, 2018
Start date
Jan 10, 2018
Primary completion
Jul 11, 2023
Completion
Jul 11, 2023
Last update
Sep 7, 2023

Study contacts

Christian Candrian, MD
study director · EOC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion